For research use only. Not for therapeutic Use.
Birtamimab（Cat No.:I042155）is an investigational monoclonal antibody designed to target and inhibit amyloid beta, a protein that forms plaques in the brain, which are a hallmark of Alzheimer’s disease. By binding to amyloid beta, birtamimab aims to prevent the formation of these plaques and potentially reduce their toxic effects on brain cells. This could help slow the progression of Alzheimer’s disease and improve cognitive function in patients. It is being studied in clinical trials to assess its safety, efficacy, and potential as a treatment for Alzheimer’s and other amyloid-related neurodegenerative diseases.
| Catalog Number | I042155 |
| CAS Number | 1608108-91-3 |
| Purity | ≥95% |
